Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison.

This study compared the clinical efficacy and safety of attention-deficit/hyperactivity disorder (ADHD) pharmacotherapy in children and adolescents 6-17 years of age. A systematic literature review was conducted to identify randomized controlled trials (RCTs) of pharmacologic monotherapies among chi...

Descripción completa

Detalles Bibliográficos
Publicado en:European Child & Adolescent Psychiatry Vol. 26; no. 8; pp. 875 - 898
Autores principales: Joseph, Alain, Ayyagari, Rajeev, Xie, Meng, Cai, Sean, Xie, Jipan, Huss, Michael, Sikirica, Vanja
Formato: meta analysis research systematic review tables/charts Journal Article
Publicado: Springer Nature Aug2017
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=124332431&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 124332431
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10188827
        EJ3
      jtl: European Child & Adolescent Psychiatry
      issn: 10188827
      maglogo: N
    pubinfo:
      dt: Aug2017
      vid: 26
      iid: 8
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        124332431
        124332431
        144057627
        124332431
        10.1007/s00787-017-0962-6
        124332431
      ppf: 875
      ppct: 23
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison.
      aug:
        au:
          Joseph, Alain
          Ayyagari, Rajeev
          Xie, Meng
          Cai, Sean
          Xie, Jipan
          Huss, Michael
          Sikirica, Vanja
        affil: Shire , Zug Switzerland
      sug:
        subj:
          Attention Deficit Hyperactivity Disorder Drug Therapy
          Psychiatric Care
          Treatment Outcomes
          Systematic Review
          Meta Analysis
          Human
          Medline
          Embase
          Psycinfo
          Cochrane Library
          CINAHL Database
          Randomized Controlled Trials
          Psychiatric Patients
          Child
          Adolescence
          Attention Deficit Hyperactivity Disorder Symptoms
          Adrenergic alpha-Agonists Therapeutic Use
          Adrenergic Uptake Inhibitors Therapeutic Use
          Central Nervous System Stimulants Therapeutic Use
          Psychological Tests
          Scales
          Severity of Illness Indices
          Child: 6-12 years
          Adolescent: 13-18 years
      ab: This study compared the clinical efficacy and safety of attention-deficit/hyperactivity disorder (ADHD) pharmacotherapy in children and adolescents 6-17 years of age. A systematic literature review was conducted to identify randomized controlled trials (RCTs) of pharmacologic monotherapies among children and adolescents with ADHD. A Bayesian network meta-analysis was conducted to compare change in symptoms using the ADHD Rating Scale Version IV (ADHD-RS-IV), Clinical Global Impression-Improvement (CGI-I) response, all-cause discontinuation, and adverse event-related discontinuation. Thirty-six RCTs were included in the analysis. The mean (95% credible interval [CrI]) ADHD-RS-IV total score change from baseline (active minus placebo) was −14.98 (−17.14, −12.80) for lisdexamfetamine dimesylate (LDX), −9.33 (−11.63, −7.04) for methylphenidate (MPH) extended release, −8.68 (−10.63, −6.72) for guanfacine extended release (GXR), and −6.88 (−8.22, −5.49) for atomoxetine (ATX); data were unavailable for MPH immediate release. The relative risk (95% CrI) for CGI-I response (active versus placebo) was 2.56 (2.21, 2.91) for LDX, 2.13 (1.70, 2.54) for MPH extended release, 1.94 (1.59, 2.29) for GXR, 1.77 (1.31, 2.26) for ATX, and 1.62 (1.05, 2.17) for MPH immediate release. Among non-stimulant pharmacotherapies, GXR was more effective than ATX when comparing ADHD-RS-IV total score change (with a posterior probability of 93.91%) and CGI-I response (posterior probability 76.13%). This study found that LDX had greater efficacy than GXR, ATX, and MPH in the treatment of children and adolescents with ADHD. GXR had a high posterior probability of being more efficacious than ATX, although their CrIs overlapped.
      pubtype: Academic Journal
      doctype:
        meta analysis
        research
        systematic review
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N